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Abstract
Background: Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma
(mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied
to assess outcomes in patients receiving T-cell checkpoint inhibitory immunotherapy and tyrosine kinase inhibitor
therapy, but have not been applied extensively to patients receiving high dose interleukin-2 (HD IL-2) immunotherapy.
Methods: Survival of 810 mRCC patients treated from 2006 to 2017 with high dose IL-2 (aldesleukin) and enrolled in the
PROCLAIMSM registry data base was assessed utilizing the International Metastatic RCC Database Consortium (IMDC) risk
criteria. Median follow-up is 23.4 months (mo.) (range 0.2–124 mo.). Subgroup evaluations were performed by separating
patients by prior or no prior therapy, IL-2 alone, or therapy subsequent to IL-2. Some patients were in two groups. We
will focus on the 356 patients who received IL-2 alone, and evaluate outcome by risk factor categories.
Results: Among the 810 patients, 721 were treatment-naïve (89%) and 59% were intermediate risk. Overall, of the 249
patients with favorable risk, the median overall survival (OS) is 63.3 mo. and the 2-year OS is 77.6%. Of 480 patients with
intermediate risk, median OS is 42.4 mo., 2-year OS 68.2%, and of 81 patients with poor risk, median OS 14 mo., 2-year OS
40.4%. Among those who received IL-2 alone (356 patients), median OS is 64.5, 57.6, and 14months for favorable,
intermediate and poor risk categories respectively. Two year survival among those treated only with HD IL-2 is 73.4, 63.7
and 39.8%, for favorable, intermediate and poor risk categories respectively.
Conclusions: Among mRCC patients treated with HD IL-2, all risk groups have median and 2-year survival consistent
with recent reports of checkpoint or targeted therapies for mRCC. Favorable and intermediate risk (by IMDC) patients
treated with HD IL-2 have longer OS compared with poor risk patients, with most durable OS observed in favorable risk
patients. Favorable risk patients treated with HD IL-2 alone have a 2-year OS of 74%. These data continue to support a
recommendation for HD IL-2 for patients with mRCC who meet eligibility criteria.
Trial registration: PROCLAIM, NCT01415167 was registered with ClinicalTrials.gov on August 11, 2011, and initiated for
retrospective data collection until 2006, and prospective data collection ongoing since 2011.
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Background
High dose aldesleukin (HD IL-2), a T-cell growth factor, is
an effective immunotherapy for metastatic melanoma
(mM) and metastatic renal cell carcinoma (mRCC), yield-
ing a 14–25% objective response rate (ORR) (complete
and partial responses) with prolonged response duration,
often decades, for complete responders [1–8]. Extensive
clinical experience and detailed management guidelines
over the last 30 years of HD IL-2 use has ensured predict-
able short term toxicity and minimal to no lasting residual
toxicity [1–9]. As the studies which led to approval for
HD IL-2 are decades old, we developed the PRO-
CLAIMSM database, a multi-institutional clinical registry
of patients treated with HD IL-2, implemented in 2011,
with retrospective data collected back to 2006 and pro-
spective data entered to the present. Seventy-five percent
of subjects have been entered prospectively. This is the
largest database of real-world outcomes of contemporary
IL-2 treatment. Multiple reports have been generated
from this database [2, 3, 6–8, 10].
Survival of patients with mRCC is heterogeneous,
but may be projected by several prognostic scoring sys-
tems based on clinically available risk factors [11–14].
Studies utilizing cytokine therapy identified the follow-
ing factors as significant for poor survival: elevated
lactate dehydrogenase, elevated calcium, anemia with
hemoglobin below lower limit of normal (LLN), the
renal tumor remaining in place during treatment for
metastatic disease, and impaired performance status
[11–15]. The International Metastatic Renal Cell Can-
cer Database Consortium (IMDC) risk criteria have
evolved from prior systems [11, 12, 15], and have been
successfully applied to assess survival outcomes among
patients treated with either anti-vascular endothelial
growth factor (VEGF) targeted therapy or immuno-
therapy [16, 17].
Prognostic scoring systems do not necessarily predict
treatment outcome and therefore it is important to as-
sess the efficacy of each new therapy in the different
prognostic groups. A recently reported randomized trial
evaluated the outcome for patients with mRCC treated
with the combination of anti-programmed death − 1
(anti-PD1) and anti-cytotoxic T-lymphocyte-associated
antigen-4 (anti-CTLA-4) checkpoint inhibitors (CPI)
compared to those treated with sunitinib [18]. Surpris-
ingly, favorable risk patients treated with CPI immuno-
therapy had a lower 18-month overall survival (OS)
compared to favorable risk patients treated with sunitinib,
but for patients with intermediate and poor risk, the re-
verse was observed [18]. In this trial’s analysis, PD-ligand1
(PD-L1) expression was not entirely predictive of CPI
benefit, leaving the observed outcome not easily explained.
The results of this trial led to FDA approval of the com-
bination of ipilimumab and nivolumab for intermediate
and poor risk mRCC patients, but not for those with
favorable risk.
In view of the above outcome of more efficacious re-
sults with sunitinib compared to CPI immunotherapy in
favorable risk mRCC patients, and because patients se-
lected for HD IL-2 treatment meet physiologic parame-
ters allowing them to tolerate treatment and are not
selected by IMDC risk criteria specifically [2, 3, 5–10],
we have interrogated the PROCLAIMSM HD IL-2 treat-
ment database for survival outcome by IMDC clinical
risk criteria of patients with mRCC treated with HD
IL-2 [10, 19]. This report represents the first analysis of
survival of mRCC patients entered into this database
utilizing the IMDC risk factors and risk categories and
evaluating their impact on survival.
Methods
All data in the PROCLAIM database was collected
under an ethics committee-approved clinical protocol
approved at all contributing clinical sites [19]. Review of
patient characteristics finds the registry patients to be
consistent with prior reports of HD IL-2 treated pa-
tients, with 75% of patients male, median age 57 years,
95% having had nephrectomy, and with 94% specified as
having a clear cell component on histology.
The IMDC risk factors for poor survival are the fol-
lowing: a) impaired performance status, b) less than 1
year interval from diagnosis to systemic treatment, c)
hemoglobin less than LLN, d) corrected serum calcium
above upper LN (ULN), e) neutrophil count above ULN,
f ) platelet count above ULN. The favorable risk patient
group has none of these risk factors; the intermediate
risk group has 1–2 risk factors, and the poor risk group
has 3 or more risk factors [16, 17].
Among 939 mRCC patients in the database, 810 pa-
tients had data for all 6 IMDC criteria. Among the 810
patients, 365 patients had no prior therapy; 414 had
therapy following IL-2, 89 had therapy prior to IL-2, and
356 had IL-2 alone, with no prior or subsequent therapy.
Some subjects were in more than one group, ie some
with no therapy prior, may have had therapy post-IL-2
or IL-2 alone. For 721 patients (89%), HD IL-2 was ini-
tial therapy for advanced mRCC.
This report focuses on those who received HD IL-2
alone to assess outcome by risk factor category (Table 1).
We provide survival data for those with sequential ther-
apies in Additional file 1: Table S1. Herein we also re-
port response to HD IL-2 and response duration for all
patients by risk categories (Table 2).
Outcome is calculated using product-limit survival es-
timates by Kaplan-Meier analysis, producing response
duration and survival curves. We evaluated the survival
outcome of mRCC patients treated with HD IL-2 by
IMDC risk category, and by treatment sequence, with
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OS calculated from initiation of IL-2 treatment in all
groups. Figure 1 presents data for those treated with
IL-2 alone by risk group. Additional file 1: Figure S1 pre-
sents data for all 810 patients and Additional file 1:
Figure S2 presents survival for those who received ther-
apy post IL-2. Additional file 1: Figures S3–S5 demon-
strate complete and partial response and stable disease
duration for all responders by risk category.
Additional file 1: Figure S6 presents OS for the small
group with therapy prior to IL-2, calculated from the
start of the initial therapy for mRCC.
Results
Among the 810 patients, approximately 25% were entered
retrospectively, and 75% were entered prospectively. The
median follow-up is 23.4months (range 0.2–124+
months). Overall, 721 patients (89%) in this registry cohort
were treatment-naїve prior to receiving IL-2 and were in
the intermediate risk category (59%).
Survival for patients treated with HD IL-2 alone
Among the 356 patients treated with HD IL-2 alone, 119
met favorable, 203 (57%) met intermediate and 34 met
poor risk criteria. This distribution is characteristic of
mRCC patients undergoing HD IL-2 or other systemic
treatment, in that more than 50% of mRCC patients
undergoing initial treatment for advanced disease are in
the intermediate risk category. Clinical factors delineating
eligibility for IL-2 therapy may somewhat increase the
proportion of favorable risk patients, however.
The median OS for favorable, intermediate and poor
risk groups treated with IL-2 alone is 64.5 months, 57.6
months, and 14months, respectively (Table 1). The
2-year OS for those treated with IL-2 alone by risk
category is 73.8, 63.7, and 39.8% respectively (Table 1).
Figure 1 presents the Kaplan-Meier OS curves for pa-
tients treated with IL-2 alone by risk categories.
Thus, the median OS observed among the favorable
risk patients is followed closely by the median OS for
those in the intermediate risk group (only 6 months dif-
ference between favorable and intermediate risk groups
for those receiving IL-2 alone). The favorable risk group
has a median survival greater than 5 years, and the inter-
mediate risk patients have a median survival 2 months
less than 5 years following IL-2 alone.
Response to HD IL-2
Among all patients with all 6 IMDC criteria known
(n = 810), 44 achieved complete response (CR)
(5.4%), 156 achieved partial response (PR) (19%), and
337 achieved stable disease (SD) (41.6%) as best re-
sponse (Table 2). Median response duration for all
CR and PR patients in favorable and intermediate
risk groups was >/= 5+ years (Additional file 1: Fig-
ures S3–S5), which is consistent with clinical trial
data demonstrating durable CR and PR results fol-
lowing treatment with HD IL-2 [5]. Favorable risk
patients achieving SD following IL-2 had median
duration of SD of 49 months and intermediate risk
SD patients had median duration of SD of 24
months.
Supplemental survival data
Survival data for all 810 IL-2 treated patients and for
the subgroups who received therapy before or after
HD IL-2 are presented in the supplemental file. Me-
dian OS and 2-year OS by risk group and treatment
sequence are presented in Additional file 1: Table S1a
and b. Additional file 1: Figure S1 shows OS by risk
category for all patients. For the 249 patients with fa-
vorable risk, the median OS is 63.3 months and the
2-year OS is 77.6%, and these results are similar when
broken down by the treatment groups. For the 480
patients with intermediate risk, median OS is 43.4
months and 2-year OS is 68.2%. Among the 81 pa-
tients with poor risk, median OS is 14 months and
2-year OS is 40.4%.
Patients treated with additional therapy following pro-
gression after HD IL-2 appeared to benefit from
follow-on therapy, and our data suggest enhanced 2-year
OS in this group, whether treated with subsequent
anti-VEGF targeted therapy (more than 80% of subse-
quent treatment) or immunotherapy (Additional file 1:
Table S1 and Figure S2). This is consistent with a previ-
ous report in smaller numbers of patients that evaluated
Table 1 Survival by risk groups of 356 patients treated with HD
IL-2 alone
Favorable Intermediate Poor
Median OS (months) (95% CI) 64.5 (39.4–112) 57.6 (34.5–62) 14 (4–58)
2 year OS from IL-2
treatment
73.8% 63.7% 39.8%
OS overall survival, 95% CI 95% confidence intervals, HD high dose,
IL-2 Interleukin-2
Table 2 Response and clinical benefit by risk category for all
patients (n = 810)
Best
response
Favorable
(n = 249)
Intermediate
(n = 480)
Poor risk
(n = 81)
CR 9 (3.6%) 34 (7%) 1 (1.2%)
PR 52 (21%) 91 (19%) 13 (16%)
SD 128 (51.4%) 185 (38.5%) 24 (30%)
PD 48 (19%) 135 (28%) 34 (42%)
Missing 12 (5%) 35 (7.3%) 9 (11%)
CR + PR 61 (24.5%) 125 (26%) 14 (17.3%)
CR + PR + SD 189 (75.9%) 310 (64.6%) 38 (46.9%)
CR complete response, PR partial response, SD stable disease, PD progressive disease
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post-IL-2 targeted therapy in patients with mRCC [6].
This could reflect a) efficacy of the subsequent therapy
independent of IL-2, b) the physiologic condition of pa-
tients eligible to receive HD IL-2 and subsequent ther-
apy, and/or c) a biological interaction between prior IL-2
therapy and ability to benefit from subsequent therapies.
Again, the limitations of registry data apply to any inter-
pretation of these data. Additionally, in this registry co-
hort, only 89 patients received therapy prior to IL-2,
again, predominantly anti-VEGF targeted therapy.
Discussion
In this analysis of mRCC patients in the PROCLAIMSM
HD IL-2 registry, all IMDC risk groups have median and
2-year survivals following HD IL-2 that are consistent
with recent reports of CPI immunotherapy or anti-VEGF
targeted therapy for mRCC. All risk categories have im-
proved survival compared with historical cytokine data
[11–15] and are consistent with data from a recent pro-
spective study, IL-2 “Select” [5] and other contemporary
reports [2–4, 6–8].
In the high dose IL-2 alone patient group, favorable
and intermediate risk patients demonstrate prolonged
OS, and many experience years of treatment-free sur-
vival following IL-2 therapy. Further, the prolonged
OS and 74% 2-year survival for the favorable risk
group treated with IL-2 alone is in contrast to the
outcome from the randomized trial of combined
checkpoint inhibition, in which the favorable risk
group had a better 18-mo OS with sunitinib com-
pared with CPI [18]. This contrast demonstrates the
nuances and differences between different categories
of immunotherapy in the treatment of mRCC that are
yet to be sorted out.
Eligibility for HD IL-2 treatment includes physiologic
evaluation which may enrich for favorable risk patients,
although the percentage of intermediate risk patients is
similar to other mRCC treatment reports. Nevertheless,
these eligibility criteria might inadvertently select an
even better subset of each IMDC risk group for outcome
when treated with IL-2 alone or with IL-2 followed by
subsequent therapy, yielding durable response and sur-
vival. In support of this concept, even poor risk patients
meeting IL-2 therapy criteria demonstrated clinical
benefit with best clinical responses of CR, PR and SD re-
ported, and 2 year OS of 40–50%.
Among responders in all treatment sequences, median
response duration (CR and PR) following HD IL-2 was
greater than or equal to 5 years regardless of risk category.
However, durable stable disease was observed primarily in
favorable risk (median > 5 years) and intermediate risk
(median > 3 years) groups, with 10% durable SD among
the poor risk group.
The CR rate of 5.4% is consistent with prior reports of
IL-2 alone, but less than that of the combination ipili-
mumab/nivolumab arm of Checkpoint 214 in first line
patients [18]. However, it is of note that the CR rate for
single agent nivolumab in mRCC in both a large clinical
Fig. 1 Overall survival by RCC risk: IL-2 alone
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trial experience and a large registry experience is 1 and
1.2%, respectively [20, 21]. Additionally, the CR plus PR
rate for HD IL-2 alone is 25%, again consistent with
prior reports of IL-2 and possibly allowing for resection
of residual disease in PR patients, yielding “surgical
CRs”, often with long-term disease-free intervals. The
CR + PR rate for nivolumab alone was reported as 25
and 20% [20, 21].
Limitations of registry data
Therapy-specific registries have helped provide real-
world data and increased safety data on therapies be-
yond the initial clinical trials leading to drug approvals,
and thus provide more insight into the spectrum of use
of therapies. Examples are the International Bone Mar-
row Transplant Registry (IBMTR), the IMDC, and the
initial registries of patients treated with anti-VEGF tar-
geted therapies for mRCC patients off protocol, follow-
ing regulatory approvals, but before general availability
of these medications. The PROCLAIM registry has pro-
vided insight into optimization of IL-2 management and
patient selection for this therapy with a goal of maximiz-
ing benefit from IL-2 [19, 22].
With decades of experience, careful patient selection
and explicit treatment eligibility criteria have enhanced
the safety and efficacy of IL-2, but such selection may
limit generalizability of conclusions. There are limita-
tions to registry data in that it may not be audited or
reviewed, relying on investigator reporting, and there are
limitations to the amount of data collectable from sites,
as well as variations in documentation, which may limit
comparability. Additionally, patients may not be enrolled
in a consecutive fashion, depending on other treatment
options or choices available at various sites.
Combination of HD IL-2 with checkpoint inhibitors,
sequential and concurrent treatment
In view of the well-known durability of response (DOR) to
HD IL-2 from many reports, and the observation of dur-
able survival of mRCC patients following HD IL-2, par-
ticularly in favorable and intermediate risk groups in this
report, combination therapy, both in sequence and con-
currently, to enhance the complete response rate, DOR
and OS is being investigated. Metastatic RCC responders
to HD IL-2 have among the most durable survival data of
mRCC patients with any treatment [2–8, 10, 12, 16–18].
A series of recent reports suggest the feasibility of combi-
nations, either sequentially or concurrently.
Safety and efficacy of HD IL-2 followed by anti-VEGF
targeted therapies for stable or progressive disease has
been previously reported from the PROCLAIM registry
data, and confirmed in this larger cohort (Additional file 1:
Table S1a, b), demonstrating enhanced OS [6]. The in-
creased use of anti-VEGF therapy and CPI therapy as initial
treatment has also led to further evaluation of sequence,
with these therapies preceding HD IL-2. As presented in
the supplemental data patients eligible to receive HD IL-2
following progression on anti-VEGF therapy have outcomes
similar to those receiving HD IL-2 alone (Additional file 1:
Table S1b).
Buchbinder et al. has published retrospective data
demonstrating activity and no additive or unexpected
toxicity among melanoma patients treated with HD IL-2
following progression after ipilimumab (Ipi) [23]. More
recently, they reported safety and efficacy of HD IL-2
treatment in patients who had previously received
anti-PD1 therapy and then progressed, (including both
melanoma and mRCC patients) with outcomes similar to
patients treated with IL-2 alone as first line therapy [24].
HD IL-2 was both active and safe in patients who had no
ongoing immune-related adverse events (iRAEs) other
than hypothyroid disease undergoing replacement therapy
[24]. A prospective evaluation of this sequence is planned.
With respect to concurrent administration of HD IL-2
and CPI therapy, early feasibility was reported by Prieto
et al. in an initial clinical study report and a 7-year
follow-up of 36 melanoma patients treated with the
combination of Ipi and HD IL-2 [25, 26]. The schedule
was dose 1 of Ipi given alone, followed by dosing every 3
weeks, as tolerated, with the combination of one dose of
Ipi and then HD IL-2 720,000 units per kilogram (U/kg)
every 8 h up to 15 doses, with the first dose of IL-2 given
within 24 h of the Ipi dose. Although initially a dose-
finding study, 24 of 36 patients were treated at 3 mg/kg
of Ipi. The CR rate (calculated among all 36 patients)
was 17%, with all CR’s ongoing at the time of the
long-term follow-up report and the longest duration be-
ing 89+ months in that report [26]. Of interest, grade
III/IV iRAEs were 17% among the Ipi/IL-2 patients, in
contrast to grade III/IV iRAE rates of 29 and 32% in two
parallel Ipi/vaccine trials conducted at the same doses
and schedules of Ipi by this group [25, 26]. Also of inter-
est, among the Ipi/IL-2 patients, there was no correl-
ation between response and development of iRAEs, but
the numbers are small. The high CR rate and tolerable
toxicity as well as the durability of responses observed,
strongly suggest that further combination studies of HD
IL-2 and CPIs should be evaluated, for the potential of
enhancing CR rate, potentially leading to durable re-
sponses and enhanced 2 year and overall survival.
Several ongoing investigator initiated trials are evaluat-
ing concurrent or rapid sequential use of HD IL-2 and
anti-PD1 agents, in both melanoma and mRCC, and are
evaluating immune parameters and biomarkers
(Additional file 1: Table S2). These studies are ongoing,
several are dose-finding for IL-2, and to date no unusual
safety signals have been reported. The clinical trial that
is furthest along is NCT02964078, in mRCC patients,
Fishman et al. Journal for ImmunoTherapy of Cancer            (2019) 7:84 Page 5 of 7
with concurrent pembrolizumab and IL-2, 600,000 U/kg,
but utilizing a different IL-2 schedule, with 5 doses ad-
ministered over 33 h, similar to a previously published
regimen [27]. Preliminary data were reported at the Feb-
ruary 2019 annual meeting of the Genitourinary Ameri-
can Society of Clinical Oncology (ASCO) and describe a
higher than additive response rate with no prohibitive
toxicity [28]. Follow-up is ongoing.
Conclusions
HD IL-2 treatment yields durable responses among
mRCC patients of all risk categories eligible for HD IL-2
therapy, and prolonged survival among mRCC patients,
particularly in the favorable and intermediate risk groups.
This therapy has the advantage of yielding prolonged
treatment-free survival among responders. Additionally,
data supporting feasibility of concurrent administration of
IL-2 with CPIs is accumulating, potentially enhancing
response rates. HD IL-2 remains an important treatment
option for mRCC patients meeting eligibility criteria, both
as first line and subsequent therapy. Combination studies
are ongoing.
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